Fidelity Select Biotechnology Portfolio Operating Income

Fidelity Select Biotechnology Portfolio (FBIOX) currently reports a operating income of $8.3M as of September 2023. That compares with $7.5M in the prior-year period — up 10.7% year over year. Use the charts on this page to explore Fidelity Select Biotechnology Portfolio's operating income history and peer comparisons.

Fidelity Select Biotechnology Portfolio's operating income increased from $7.5M to $8.3M — a 10.7% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fidelity Select Biotechnology Portfolio reported $8.3M in operating income as of September 2023. That compares with $7.5M in the prior-year period — up 10.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $8.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fidelity Select Biotechnology Portfolio, and consider following FBIOX for alerts when major investors trade the stock.